Complement 3 Glomerulopathy (C3G) Market

Jul 30, 2020

10 likes | 14 Vues

The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in 2017 was 8,175 in the seven major markets. In 2017, the United States accounted for the highest diagnosed prevalent cases of C3G with 3,967 cases. The market size of Complement 3 Glomerulopathy (C3G) in 7MM was USD 40.6 Million in 2017, which is expected to increase during the study period 2017-2030. Intermediate pipeline activity, increasing disease awareness, and the advent of biomarkers in near future are some of the key factors expected to drive the C3G market forward in the coming years. The key players in the Complement 3 Glomerulopathy (C3G) Market include Alexion Pharmaceuticals, Omeros, Apellis Pharma, Novartis and many others. For more details visit: https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market

DelveInsight

Télécharger la présentation

Complement 3 Glomerulopathy (C3G) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D